Repository logo
  • English
  • 中文
  • Log In
    New user? Click here to register.Have you forgotten your password?
Repository logo
    Communities & Collections
    Research Outputs
    Fundings & Projects
    People
    Organizations
    Statistics
  • English
  • 中文
  • Log In
    New user? Click here to register.Have you forgotten your password?
  1. Home
  2. Chung Shan Medical University
  3. Pure學術人才庫轉入
  4. Adding gentamicin to fluoroquinolone-based antimicrobial prophylaxis reduces transrectal ultrasound-guided prostate biopsy-related infection rate
 
  • Details
Options

Adding gentamicin to fluoroquinolone-based antimicrobial prophylaxis reduces transrectal ultrasound-guided prostate biopsy-related infection rate

Journal
Urological Science
Date Issued
2016-06-01
Author(s)
YZUO-YI HSIEH  
SHAO-CHUAN WANG  
WEN-JUNG CHEN  
SUNG-LANG CHEN  
DOI
10.1016/j.urols.2015.04.008
URI
https://www.scopus.com/pages/publications/84930702661
https://scholars.csmu.edu.tw/handle/123456789/28161
Abstract
Objective Transrectal ultrasound-guided prostate (TRUS) biopsy is the standard method for the diagnosis of prostate cancer. Quinolone-based prophylaxis before a TRUS biopsy of the prostate is the most common regimen worldwide. In this retrospective study, we evaluated the efficacy and cost effectiveness of adding gentamicin to a fluoroquinolone-based prophylaxis regimen. Materials and methods In total, our study included 263 patients classified into two groups. Group 1 consisted of 129 patients who received one oral dose of levofloxacin (500 mg) daily 2 days before the biopsy, on the day of the biopsy, and for 2 days after the biopsy. Group 2 consisted of 134 patients who received a single intramuscular (IM) gentamicin injection (80 mg) 30 minutes before the biopsy in addition to the same oral levofloxacin protocol as Group 1. We recorded and analyzed data including age, indication for a TRUS biopsy of the prostate, prostate volume, comorbidity, infectious complications, and blood and urine culture results. Results The mean prostate-specific antigen level was 38.6 ng/mL ± 312.9 ng/mL (range, 4.4–2626 ng/mL) in Group 1, and 34.8 ng/mL ± 127.1 ng/mL (range, 2.11–1423 ng/mL) in Group 2. The groups were similar in terms of mean age, indication for a biopsy, prostate volume, number of biopsy cores taken, and comorbidities. Infection-related complications occurred in eight of 129 (6.2%) and in one of 134 (0.74%) patients in Groups 1 and 2, respectively (p = 0.02). Conclusion The addition of IM gentamicin (80 mg) was beneficial in improving the efficacy of fluoroquinolone and reducing the post-TRUS biopsy infection rate. Gentamicin is relatively inexpensive and readily available in daily practice and has good compliance for patient use.
Type
journal article
Make it your own

DSpace-CRIS can be extensively configured to meet your needs. Decide which information need to be collected and available with fine-grained security. Start updating the theme to match your Institution's web identity.

Built with DSpace-CRIS software - Extension maintained and optimized by 4Science

  • Cookie settings
  • Privacy policy
  • End User Agreement
  • Send Feedback